Natalizumab (Tysabri ®) is a humanized monoclonal antibody against the cellular adhesion molecule α4-integrin. Natalizumab is used in the treatment of multiple sclerosis and Crohn's disease.

Natalizumab is expected to come off-patent in 2015 and already many companies are developing biosimilar versions of Tysabri.

We have long-standing experience in the analysis of different variants of Tysabri originators and biosimilars.

To support the analytical development of Tysabri biosimilars or biobetters, Protagen has set up an analysis program in accordance with ICH Q6B guidelines, including method setup, validation of customer-specific methods, and release testing. This package includes protein quantification, characterizing the protein primary structure, analysis of N- glycosylation and protein modifications.

Specific BioAssay for Natalizumab provided by a strategic partner:

  • Target: α4-integrin Assay type: Binding Assay (flow cytometry), statistical analysis by PLA

Your contact for Natalizumab at Protagen Protein Services GmbH

Martin-Blueggel 150x100px

Martin Blüggel

Chief Executive Officer (CEO)
Our business development team will be happy to assist you with your project.

Phone: +49 (0) 231 9742-6100